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As the field moves towards earlier interventions in precli-
nical stages of AD or even envisions true primary preven-
tion strategies, the therapeutic strategies employed must
be “safe enough”. Whether any current therapeutic (e.g.,
b-secretase inhibitors, g-secretase modulators (GSM) or
anti-Ab immunotherapies) being tested for disease modi-
fication is sufficiently safe is not known. In order to try
and identify “safe enough” therapeutics, we have been
evaluating whether endogenous regulators of Ab can be
harnessed as therapeutics. We have identified a cholesterol
metabolite, cholestenoic acid (CA), as potent GSM, and
have genetic data from mice that are consistent with a role
for CA in regulating Ab42 levels in the brain. We will
discuss our ongoing studies exploring how we might
utilize CA or the CA metabolic pathway to safely lower
Ab42 levels. In addition, we have been evaluating how we
can use soluble forms of endogenous innate immune
receptors to alter Ab deposition and modulate neuroin-
flammation in mouse models of AD. We have also been
exploring the utility of such strategy in other neurodegen-
erative models. Effects of soluble toll-like receptors and
soluble TREM2 will be presented. Our current data estab-
lish that soluble TLR4 and 5 both dramatically inhibit
Ab deposition but that soluble TLR2 and 6 do not. We
also have data that suggest the utility of these soluble
receptors in a-synucleinopathies. By using endogenous
metabolites and receptors, we hope that the likelihood of
adverse toxicities will be diminished and that these or
endogenous factors can be safely developed for prophylactic
or early intervention in AD and perhaps other neurodegen-
erative disorders.
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